Cargando…
Complete remission with ibrutinib after allogeneic stem cell transplant for central nervous system relapse of mantle cell lymphoma: A case report and literature review
Central nervous system (CNS)‐relapsed mantle cell lymphoma (MCL) is a rare, aggressive non‐Hodgkin lymphoma without a standard treatment. Ibrutinib has shown promising results for inducing remission in other non‐Hodgkin lymphomas and may be considered as successful treatment for CNS‐relapsed MCL in...
Autores principales: | Rich, Jessica D., Clark, Stephen M., Fedoriw, Yuri, Jewells, Valerie, Wood, William, Dittus, Christopher |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6787781/ https://www.ncbi.nlm.nih.gov/pubmed/31624617 http://dx.doi.org/10.1002/ccr3.2257 |
Ejemplares similares
-
Ibrutinib Plus R-ICE Induces Remission in Blastoid Variant Mantle Cell Lymphoma with CNS Relapse
por: Oh, Timothy S., et al.
Publicado: (2022) -
Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma and Chronic Lymphocytic Leukemia
por: Peterson, Derek, et al.
Publicado: (2014) -
Ibrutinib Treatment of Mantle Cell Lymphoma Relapsing at Central Nervous System: A Case Report and Literature Review
por: Mannina, Donato, et al.
Publicado: (2017) -
Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
por: Maruyama, Dai, et al.
Publicado: (2016) -
Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma
por: Portell, Craig A., et al.
Publicado: (2022)